CCR5 and metabolic dysfunction-associated steatotic liver disease: Our result surprisingly showed that CCR5 blockade significantly reduced the Mpo expression in g-MDSCs under the NAFLD microenvironment (Figure S3), suggesting a potential strategy to ameliorate liver damage targeting CCR5 on g-MDSCs.